Supernus Pharmaceuticals Retained Earnings (Accumulated Deficit) 2011-2024 | SUPN

Supernus Pharmaceuticals retained earnings (accumulated deficit) from 2011 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Supernus Pharmaceuticals Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $483
2022 $481
2021 $380
2020 $326
2019 $200
2018 $86
2017 $-27
2016 $-84
2015 $-176
2014 $-189
2013 $-179
2012 $-86
2011 $-40
2010 $
Supernus Pharmaceuticals Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $541
2024-06-30 $503
2024-03-31 $483
2023-12-31 $483
2023-09-30 $481
2023-06-30 $497
2023-03-31 $498
2022-12-31 $481
2022-09-30 $456
2022-06-30 $454
2022-03-31 $446
2021-12-31 $380
2021-09-30 $377
2021-06-30 $356
2021-03-31 $332
2020-12-31 $326
2020-09-30 $296
2020-06-30 $256
2020-03-31 $221
2019-12-31 $200
2019-09-30 $166
2019-06-30 $138
2019-03-31 $105
2018-12-31 $86
2018-09-30 $61
2018-06-30 $33
2018-03-31 $2
2017-12-31 $-27
2017-09-30 $-40
2017-06-30 $-56
2017-03-31 $-74
2016-12-31 $-84
2016-09-30 $-99
2016-06-30 $-160
2016-03-31 $-171
2015-12-31 $-176
2015-09-30 $-182
2015-06-30 $-186
2015-03-31 $-189
2014-12-31 $-189
2014-09-30 $-193
2014-06-30 $-191
2014-03-31 $-194
2013-12-31 $-179
2013-09-30 $-156
2013-06-30 $-132
2013-03-31 $-105
2012-12-31 $-86
2012-09-30 $-73
2012-06-30 $-59
2012-03-31 $-49
2011-12-31 $-40
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.089B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00